Heron Therapeutics, Inc. (FRA:AXD2)

Heron Therapeutics Statistics

Total Valuation

FRA:AXD2 has a market cap or net worth of EUR 181.39 million. The enterprise value is 261.23 million.

Market Cap	181.39M
Enterprise Value	261.23M

Important Dates

The next estimated earnings date is Friday, February 27, 2026.

Earnings Date	Feb 27, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	183.36M
Shares Outstanding	n/a
Shares Change (YoY)	+3.91%
Shares Change (QoQ)	+10.60%
Owned by Insiders (%)	0.79%
Owned by Institutions (%)	56.86%
Float	131.91M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.37
PB Ratio	14.30
P/TBV Ratio	30.30
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 52.77, with an EV/FCF ratio of -9.84.

EV / Earnings	-22.57
EV / Sales	1.96
EV / EBITDA	52.77
EV / EBIT	190.16
EV / FCF	-9.84

Financial Position

The company has a current ratio of 2.56, with a Debt / Equity ratio of 9.44.

Current Ratio	2.56
Quick Ratio	1.52
Debt / Equity	9.44
Debt / EBITDA	24.40
Debt / FCF	-4.51
Interest Coverage	0.21

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	0.42%
Return on Invested Capital (ROIC)	0.68%
Return on Capital Employed (ROCE)	1.00%
Revenue Per Employee	1.08M
Profits Per Employee	-94,857
Employee Count	122
Asset Turnover	0.66
Inventory Turnover	0.90

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -12.21% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-12.21%
50-Day Moving Average	1.02
200-Day Moving Average	1.51
Relative Strength Index (RSI)	50.85
Average Volume (20 Days)	17

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	21.09

Income Statement

In the last 12 months, FRA:AXD2 had revenue of EUR 132.19 million and -11.57 million in losses. Loss per share was -0.07.

Revenue	132.19M
Gross Profit	87.60M
Operating Income	1.36M
Pretax Income	-11.57M
Net Income	-11.57M
EBITDA	3.37M
EBIT	1.36M
Loss Per Share	-0.07

Balance Sheet

The company has 47.29 million in cash and 119.70 million in debt, giving a net cash position of -72.41 million.

Cash & Cash Equivalents	47.29M
Total Debt	119.70M
Net Cash	-72.41M
Net Cash Per Share	n/a
Equity (Book Value)	12.69M
Book Value Per Share	0.03
Working Capital	119.06M

Cash Flow

In the last 12 months, operating cash flow was -25.73 million and capital expenditures -813,947, giving a free cash flow of -26.54 million.

Operating Cash Flow	-25.73M
Capital Expenditures	-813,947
Free Cash Flow	-26.54M
FCF Per Share	n/a

Margins

Gross margin is 66.27%, with operating and profit margins of 1.03% and -8.75%.

Gross Margin	66.27%
Operating Margin	1.03%
Pretax Margin	-8.75%
Profit Margin	-8.75%
EBITDA Margin	2.55%
EBIT Margin	1.03%
FCF Margin	n/a

Dividends & Yields

FRA:AXD2 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.91%
Shareholder Yield	-3.91%
Earnings Yield	-6.38%
FCF Yield	-14.63%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on January 13, 2014. It was a reverse split with a ratio of 0.05.

Last Split Date	Jan 13, 2014
Split Type	Reverse
Split Ratio	0.05

Scores

FRA:AXD2 has an Altman Z-Score of -8.87 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-8.87
Piotroski F-Score	5